UPB (Upstream Bio) Marketable Securities : $144.56 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Upstream Bio's Marketable Securities for the quarter that ended in Dec. 2024 was $144.56 Mil.

Upstream Bio's annual Marketable Securities increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($83.98 Mil) and increased from Dec. 2023 ($83.98 Mil) to Dec. 2024 ($144.56 Mil).

Upstream Bio Marketable Securities Historical Data

The historical data trend for Upstream Bio's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Marketable Securities Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Marketable Securities

83.98

144.56

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Marketable Securities	Get a 7-Day Free Trial			-	83.98	188.47	187.71	144.56

Upstream Bio Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Upstream Bio (NAS:UPB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Upstream Bio Marketable Securities Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.